Paracetamol metabolism and related genetic differences

Drug Metabolism Reviews

Volumn 43, Issue 1, 2011, Pages 41-52

  Zhao, Lizi ^a,b   Pickering, Giséle ^b,c,d  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c INSERM   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Acetaminophen; drug metabolism; intersubject differences; pharmacogenetics; toxicity

Indexed keywords

ACYLTRANSFERASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 3; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; FATTY ACID AMIDASE; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A6; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; N ACETYL 1,4 BENZOQUINONE IMINE; P AMINOPHENOL; PARACETAMOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFATE; SULFOTRANSFERASE; SULFOTRANSFERASE 1A1; TOXIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AEROBIC METABOLISM; AFRICAN AMERICAN; ANALGESIA; ASIAN; CAUCASIAN; DEACETYLATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG SULFATION; ENZYME ACTIVITY; ETHNIC DIFFERENCE; ETHNICITY; EUROPEAN AMERICAN; GENETIC DIFFERENCE; GENOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER NECROSIS; LIVER TOXICITY; MISSENSE MUTATION; NEPHROTOXICITY; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; THALASSEMIA;

ACETAMINOPHEN; AMIDOHYDROLASES; ANTIPYRETICS; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC VARIATION; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; HUMANS; LIVER; MOLECULAR STRUCTURE; SULFOTRANSFERASES;

EID: 79951916380     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2010.527984     Document Type: Review

References (123)

1. Adjei, A. A., Gaedigk, A., Simon, S. D., Weinshilboum, R. M., Leeder, J. S. (2008). Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res (Part A) 82:155-165. (Pubitemid 351458137)
2. Aleksunes, L. M., Campion, S. N., Goedken, M. J., Manautou, J. E. (2008). Acquired resistance to acetaminophen hepatotoxicity is associated with induction of multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes. Toxicol Sci 104:261-273. (Pubitemid 352038249)
3. Bailey, L. R., Roodi, N., Verrier, C. S., Yee, C. J., Dupont, W. D., Parl, F. F. (1998). Breast cancer risk and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. Cancer Res 58:65-70. (Pubitemid 28027718)
4. Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., Leone, S. (2006). Paracetamol: new vistas of an old drug. CNS Drug Rev 12(3-4):250-275. (Pubitemid 46047791)
5. Bessems Jos, G. M., Vermeulen Nico, P. E. (2001). Paracetamol (acetaminophen)-induced toxicity: molecular and biochemical mechanisms. Analogues and protective approaches Crit Rev Toxicol 31(1):55-138.
6. Borne, R. F. (1995). Nonsteroidal anti-infammatory drugs. In: Foye, W. O., Lemke, T. L., Williams, D. A., (Eds.), Principles of medicinal chemistry, fourth edition (pp 544-545). Baltimore, Maryland, USA: Williams & Wilkins.
7. Bradford, L. D. (2002). CYP2D6 allele frequency in European Caucasians, Asians, Africans, and their descendants. Pharmacogenomics 2002; 3(2):229-243. (Pubitemid 34223859)
8. Bridger, S., Henderson, K., Glucksman, E., Ellis, A. J., Henry, J. A., Williams, R. (1998). Deaths from low-dose paracetamol poisoning. BMJ 316:1724-1725.
9. Carlini, E. J., Raftogianis, R. B., Wood, T. C., Jin, F., Zheng, W., Rebbeck, T. R., et al. (2001). Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese, and African-American subjects. Pharmacogenetics. 2001; 11:57-68. (Pubitemid 32108662)
10. Chandrasekharan, NV, Dai, H, Roos, KLT, Evanson, NK, Tomsik, J, Elton, TS, et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99:13926-13931. (Pubitemid 35215482)
11. Chen, C. L., Liu, Q., Relling, M. V. (1996). Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 6:187-191. (Pubitemid 26151949)
12. Chen, W., Koenigs, L. L., Tompson, S. J., Peter, R. M., Rettie, A. E., Trager, W. F., et al. (1998). Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovi-rus-expressed and purifed human cytochromes P450 2E1 and 2A6. Chem Res Toxicol 11:295-301. (Pubitemid 28194352)
13. Chiang, K., Gerber, A. L., Sipe, J. C., Cravatt, B. F. (2004). Reduced cellular expression and activity of the P129T mutant of human fatty acid, amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet 13:1-7.
14. Cho, G. J., Lee, S. Y., Ki, C. H., Kim, J. W. (2005). GSTM1, GSTT1, and GSTP1 polymorphisms in the Korean population. J Kor Med Sci 20:1089-1092.
15. Ciotti, M., Marrone, A., Potter, C., Owens, I. S. (1997). Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics 7:485-495. (Pubitemid 27517577)
16. Coles, B., Wilson, I., Wardman, P., Hinson, J. A., Nelson, S. D., Ketterer, B. (1988). Te spontaneous and enzymatic reaction of N-acetyl-p-benzoquinonimine with glutathione: a stopped-fow kinetic study. Arch Biochem Biophys 264:253-260.
17. Coughtrie, M. (2002). Sulfation through the looking glass-recent advances in ulfotransferase research for the curious. Pharmacogenomics J 2:297-308. (Pubitemid 35439472)
18. Critchley, J. A. J. H., Critchley, L. A. H. P., Anderson, J., Tomlinson, B. (2005). Diferences in the single-oral-dose pharmacokinetics and urinary excretion of paracetamol and its conjugates between Hong Kong Chinese and Caucasian subjects. J Clin Pharm Ter 30:179-184. (Pubitemid 41583614)
19. Critchley, J. A. J. H., Nimmo, G. R., Gregson, C. A., Woolhouse, N. M., Precott, L. F. (1986). Intersubject and ethnic diferences in paracetamol metabolism. Br J Clin Pharmacol 22:649-657. (Pubitemid 17199003)
20. Court, M. H., Duan, S. X., Moltke, L. L. V., Greenblatt, D. J., Patten, C. J., Miners, J. O., et al. (2001). Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identif-cation of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ter 299:998-1006. (Pubitemid 33104971)
21. Dahlin, D. C., Miwa, G. T., Lu, A. Y., Nelson, S. D. (1984). N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen. Proc Natl Acad Sci USA 81:1327-1331. (Pubitemid 14173462)
22. De Morais, S. M., Chow, S. Y., Wells, P. G. (1992a). Biotransformation and toxicity of acetaminophen in congenic RHA rats with or without a hereditary defciency in bilirubin UDP-glucuronosyltransferase. Toxicil Appl Pharmacol 117:81-87.
23. De Morais, S. M., Uetrecht, J. P., Wells, P. G. (1992b). Decreased glu-curonidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 102:577-586.
24. De Morais, S. M., Wells, P. G. (1988). Defciency in bilirubin UDP-glucuronyl transferase as a genetic determinant of acetaminophen toxicity. J Pharmacol Exp Ter 247:323-331.
25. Dong, H., Haining, R. L., Tummel, K. E., Rettie, A. E., Nelson, S. D. (2000). Involvement of human cytochrome P450 2D6 in the bioactivation of acetaminophen. Drug Metab Dispos 28:1397-1400.
26. Eaton, D. L., Bammler, T. K. (1999). Concise review of the glutathione S-transferases and their signifcance to toxicology. Toxicol Sci 49:156-164. (Pubitemid 29300401)
27. Fischer, V., West, P. R., Nelson, S. D., Harvison, P. J., Mason, R. P. 1985 Formation of 4-aminophenoxyl free radical from the acetaminophen metabolite N-acetyl-p-benzoquinone imine. J Biol Chem 260 11446-11450. (Pubitemid 16252135)
28. Flanagan, Jonathan M, Gerber, Alexandra L, Cadet, Jean Lud, Beutler, Ernest, Sipe, Jack C. (2006). Te fatty acid amide, hydrolase 385 A/A (P129T), variant: haplotype analysis of an ancient missense mutation and validation of risk for drug addiction. Hum Genet 120:581-588.
29. Furman, K. D., Grimm, D. R., Mueller, T. (2004). Impact of CYP2D6 intermediate metabolizer alleles on single-dose desipramine pharmacokinetics. Pharmacogenetics 14:279-284. (Pubitemid 38638914)
30. Garte, S., Gaspari, L., Alexandrie, A. K., Ambrosone, C., Autrup, H., Autrup, J. L., et al. (2001). Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10:1239-1248. (Pubitemid 34027754)
31. Girard, H., Villeneuve, L., Court, M. H., Fortier, L. C., Caron, P., Hao, Q., et al. (2006). Te novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamp-tothecin glucuronidation levels in the liver. Drug Metab Dispos 34:1220-1228.
32. Glatt, H. (2000). Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 129:141-170. (Pubitemid 32061058)
33. Gonzalez, F. J. (2007). CYP2E1. Drug Metab Dispos 35:1-8.
34. Molinof, P. B., Ruddon, R. W. (Eds.). (1997). Goodman & Gilman's Te Pharmacological Basis of Terapeutics. Ninth ed. New York: McGraw-Hill.
35. Harrill, A. H., Watkins, P. B., Su, S., Ross, P. K., Harbourt, D. E., Stylianou, I. M., et al. (2009). Mouse population-guided rese-quencing reveals that variants in CD44 contribute to aceta-minophen-induced liver injury in humans. Genome Res 19:1507-1515.
36. Hanson, K. (2010). A pill problem: prescription drug abuse is the fastest growing form of substance abuse. State Legis 36:22-25.
37. Harries, L. W., Stubbins, M. J., Forman, D., Howard, G. C. W., Wolf, C. R. (1997). Identifcation of genetic polymorphism at the glu-tathione S-transferase P locus and association with susceptibility to bladder, testicular, and prostate cancer. Carcinogenesis 18: 641-644. (Pubitemid 28132446)
38. Haufroid, V., Buchet, J. P., Gardinal, S., Lison, D. (2002). Cytochrome P4502E1 phenotyping and the measurement of the chlorzoxazone metabolic ratio: assessment of its usefulness in workers exposed to styrene. Int Arch Occup Environ Health 75:453-458. (Pubitemid 36075138)
39. Hayashi, S., Watanabe, J., Kawajiri, K. (1991). Genetic polymorphisms in the 5 -Xanking region change transcriptional regulation of the human cytochrome P450IIEI gene. J Biochem 110:559-565.
40. Heard, K. J. (2008). Acetylcysteine for acetaminophen poisoning. NEJM 359:285-292.
41. Hebbring, SJ, Adjei, AA, Baer, JL, Jenkins, GD, Zhang, JP, Cunningham, JM, et al. (2007). Human SULT1A1 gene: copy number diferences and functional implications. Hum Mol Genet 16:463-470. (Pubitemid 46522610)
42. Henderson, C. J., Wolf, C. R., Kitteringham, N., Powell, H., Otto, D., Park, B. K. (2000). Increased resistance to acetaminophen hepa-totoxicity in mice lacking glutathione S-transferase pi. Proc Natl Acad Sci USA 97:12741-12745.
43. Hildebrandt, M. A., Salavaggione, O. E., Martin, Y. N., Flynn, H. C., Jalal, S., Wieben, E. D., et al. (2004). Human SULT1A3 pharma-cogenetics: gene duplication and functional genomic studies. Biochem Biophys Res Commun 321:870-878. (Pubitemid 39044390)
44. Hinson, J. A., Pohl, L. R., Gillette, J. R. (1979). N- hydroxyacetaminophen: a microsomal metabolite of N-hydroxyphenacetin but apparently not of acetaminophen. Life Sci 24:2133-2138. (Pubitemid 9208444)
45. Hinson, J. A. (1980). Biochemical toxicology of acetaminophen. Rev Biochem Toxicol 2:103-129.
46. Hinson, J. A., Roberts, D. W., Benson, R. W., Dalhof, K., Loft, S., Poulsen, H. E. (1990). Mechanism of paracetamol toxicity. Lancet 335:732-732.
47. Hinson, J. A., Roberts, D. W., James, L. P. (2010). Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol 196:369-405.
48. Hinz, B., Cheremina, O., Brune, K. (2008). Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J 22:383-390. (Pubitemid 351225574)
49. Högestätt, E. D., Jonsson, B. A., Ermund, A., Andersson, D. A., Bjork, H., Alexander, J. P., et al. (2005). Conversion of acetaminophen to the bioactive N-acylphenolamine, AM404, via fatty acid amide hydrolasedependent arachidonic acid conjugation in the nervous system. J Biol Chem 280:31405-31412. (Pubitemid 41291881)
50. Hosokawa, M, Furihata, T, Yaginuma, Y, Yamamoto, N, Watanabe, N, Tsukada, E, et al. (2008). Structural organization and characterization of the regulatory element of the human carboxylesterase (CES1A1 and CES1A2) genes. Drug Metab Pharmacokinet 23: 73-84.
51. Ghanem, C. I., Ruiz, M. L., Vilanueva, S. S., Luquita, M. G., Catania, V. A., Jones, B., et al. (2005). Shift from biliary to urinary elimination of acetaminophen-glucuronide in acetaminophen-pretreated rats. J Pharmacol Exp Ter 315:987-995. (Pubitemid 41635384)
52. James, L. P., Mayeux, P. R., Hinson, J. A. (2003). Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 31:1499-1506. (Pubitemid 37466918)
53. Jalan, R., Williams, R., Bernuau, J. (2006). Paracetamol: are therapeutic doses entirely safe? Lancet 368:2195-2196. (Pubitemid 44959000)
54. Jones, A. (2002). Over-the-counter analgesics: a toxicology perspective. Am J Ter 9:245-257.
55. Jones, A. L., Hagen, M., Coughtrie, M. W., Roberts, R. C., Glatt, H. (1995). Human platelet phenolsulfotransferases: cDNA cloning, stable expression in V79 cells, and identifcation of a novel allelic variant of the phenol-sulfating form. Biochem Biophys Res Commun 208:855-862.
56. Josephy, D. P. (2005). Te molecular toxicology of acetaminophen. Drug Metab Rev 37:581-594.
57. Kato, S., Shields, P. G., Caporaso, N. E., Hoover, R. N., Trump, B. F., Sugimura, H., et al. (1992). Cytochrome P4502E1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 52:6712-6715.
58. Kirchheiner, J., Sasse, J., Meineke, I., Roots, I., Brockmöller, J. (2003). Trimipramine pharmacokinetics after intravenous and oral administration in carriers CYP2D6 genotypes predicting poor, extensive, and ultrahigh activity. Pharmacokinetics 13:721-728. (Pubitemid 38429250)
59. Kis, B., Snipes, J. A., Busija, D. W. (2005). Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fctions, and uncertainties. J Pharmacol Exp Ter 315:1-7. (Pubitemid 41380491)
60. Kitteringham, N. R., Powell, H., Jenkins, R. E., Hamlett, J., Lovatt, C., Elsby, R., et al. (2003). Protein expression profling of glutath-ione S-transferase pi null mice as a strategy to identify potential markers of resistance to paracetamol-induced toxicity in the liver. Proteomics 3:191-207. (Pubitemid 36254602)
61. Laine, J. E., Auriola, S., Pasanen, M., Juvonen, R. O. (2009). Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica 39:11-21.
62. Lampe, J. W., Bigler, J., Horner, N. K., Potter, J. D. (1999). UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships toserum bilirubin concentrations. Pharmacogenetics 9:341-349. (Pubitemid 29376378)
63. Larson, AM, Polson, J, Fontana, RJ, Davern, TJ, Lalani, E, Hynan, LS, et al., and the Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42:1364-1372.
64. Lee, H. S., Ti, T. Y., Koh, Y. K., Prescott, L. F. (1992). Paracetamol elimination in Chinese and Indians in Singapore. Eur J Clin Pharmacol 43:81-84.
65. Lee, S. S. T., Buters, J. T. M., Pineau, T., Fernandez-Salguero, P., Gonzalez, F. J. (1996). Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063-12067. (Pubitemid 26157285)
66. Lohmann, W., Karst, U. (2008). Biomimetic modeling of oxidative drug metabolism. Strategies, advantages, and limitations. Anal Bioanal Chem 391:79-96.
67. Mallet, C., Daulhac, L., Bonnefont, J., Ledent, C., Etienne, M., Chapuy, E., et al. (2008). Endocannabinoid and serotonergic systems are needed for acetaminophen-induced analgesia. Pain 139:190-200.
68. Manautou, JE, Hoivik, DJ, Tveit, A, De Waart, DR, Zelcer, N, Goedken, M, et al. (2005). Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. Hepatology 42:1091-1098. (Pubitemid 43112676)
69. Manyike, P. T., Kharasch, E. D., Kalhorn, T. F., Slattery, J. T. (2000). Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ter 67:275-282. (Pubitemid 30176386)
70. Meredith, T. J., Prescott, L. F., Vale, J. A. (1986). Editorial: why do patients still die from paracetamol poisoning. Br Med J 293:345-346. (Pubitemid 16034115)
71. Miners, J. O., McKinnon, R. A., Mackenzie, P. I. (2002). Genetic polymorphisms of UDP-glucuronosyltransferases and their functional signifcance. Toxicology 181-182:453-456.
72. Mitchell, J. R., Torgeirsson, S. S., Potter, W. Z., Jollow, D. J., Keiser, H. (1974). Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ter 16:676-684.
73. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Gillette, J. R., Brodie, B. B. (1973). Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ter 187:211-217.
74. Mottino, A. D., Catania, V. A. (2008). Hepatic drug transporters and nuclear receptors: regulation by therapeutic agents. World J Gastroenterol 14:7068-7074.
75. Mugford, C. A., Tarlof, J. B. (1997). Te contribution of oxidation and deacetylation to acetaminolphen nephrotoxicity in female Sprague-Dawley rats. Toxicol Lett 93:15-22. (Pubitemid 27427504)
76. Nagar, S., Walther, S., Blanchard, R. L. (2006). Sulfotransferase (SULT) 1A1 polymorphic variants *1, *2, and *3 are associated with altered enzymatic activity, cellular phenotype, and protein degradation. Mol Pharmacol 69:2084-2092. (Pubitemid 43894328)
77. Naoe, T., Takeyama, K., Yokozawa, T., Kiyoi, H., Seto, M., Uike, N., et al. (2000). Analysis of genetic polymorphism in NQ01, GSTM1, GSTT1, and CYP3A4 in 469 Japanese patients with therapy-related leukemic/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6:4091-4095.
78. Nelson, S. D., Bruschi, S. A. (2007). Mechanisms of acetaminophen-induced liver disease. In: Kaplowitz N., Deleve, L. D. (Eds.), drug-induced liver disease, second ed. (pp 287-326. New York: Informa Healthcare.
79. Nelson, S. D., Forte, A. J., Dahlin, D. C. (1980). Lack of evidence for N-hydroxyacetaminophen as a reactive metabolite of acetaminophen in vitro. Biochem Pharmacol 29:1617-1620. (Pubitemid 10101924)
80. Newton, J. F., Bailie, M. B., Hook, J. B. (1983). Acetaminophen neph-rotoxicity in the rat. Renal metabolic activation in vitro. Toxicol Appl Pharmacol 70:433-444. (Pubitemid 14226982)
81. Newton, J. F., Kuo, C. H., De Shone, G. M., Hoefe, D. F., Bernstein, J., Hook, J. B. (1985). Te role of p-aminopheno1 in acetaminophen-induced nephrotoxicity: efect of bis(p-nitrophenyl) phosphate on acetaminophen and paminophenol nephrotoxicity and metabolism in Fischer 344 rats. Toxicol Appl Pharmacol 81:416-430. (Pubitemid 16185191)
82. Nicholls, A. W., Caddick, S. C., Wilson, I. D., Farrant, R. D., Lindon, J. C., Nicholson, J. K. (1995). High-resolution NMR spec-troscopic studies on the metabolism and futile deacetyla-tion of 4-hydroxyacetanilide in the rat. Biochem Pharmacol 49:1154-1164.
83. Nicholls, A. W., Farrant, R. D., Shockcor, J. P., Unger, S. E., Wilson, I. D., Lindon, J. C., et al. (1997). NMR and HPLC-NMR spectroscopic studies of futile deacetylation in paracetamol metabolites in rat and man. J Pharmaceut Biomed Anal 15:901-910. (Pubitemid 27199538)
84. Oyama, T., Kawamato, T., Mizoue, T., Sugio, K., Kodama, Y., Mitsudomi, T., et al. (1997). Cytochrome P4502E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 17:583-588.
85. Patel, M., Tang, B. K., Kalow, W. (1992). Variability of acetaminophen metabolism in Caucasians and Orientals. Pharmacogenetics 2:38-45.
86. Patten, C. J., Tomas, P. E., Guy, R. L., Lee, M. L., Gonzalez, F. J., Guengerich, F. P., et al. (1993). Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxico 16:511-518. (Pubitemid 23212521)
87. Persson, I., Johansson, I., Lou, Y. C., Yue, Q. Y., Duan, L. S., Bertilsson, L., et al. (1999). Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese kung cancer patients. Int J Cancer 81:325-329. (Pubitemid 29165187)
88. Peters, W. H., Te Morsche, R. H., Roelofs, H. M. (2003). Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: implications for patients with Gilbert's syndrome. J Hepatol 38:3-8. (Pubitemid 36078517)
89. Pickering, G., Estève, V., Loriot, M. A., Eschalier, A., Dubray, C. (2008). Acetaminophen reinforces descending inhibitory pain pathways. Clin Pharmacol Ter 84:47-51. (Pubitemid 351861483)
90. Pickering, G., Loriot, M. A., Libert, F., Eschalier, A., Beaune, P., Dubray, C. (2006). Analgesic efect of acetaminophen in humans: frst evidence of a central serotonergic mechanism. Clin Pharmacol Ter 79:371-378.
91. Prescott, L. F. (1983). Paracetamol overdosage: pharmacological considerations and clinical management. Drugs 25:290-314. (Pubitemid 13116577)
92. Prescott, L. F., Critchley, J. A. J. H. (1983). Te treatment of acetaminophen poisoning. Annu Rev Pharmacol Toxicol 23:87-101.
93. Prescott, L. F. (1996). Paracetamol (acetaminophen): a critical bibliographic review. London: Taylor and Francis.
94. Qiu, Y., Benet, L. Z., Burlingame, A. L. (1998). Identifcation of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J Biol Chem 273:17940-17953. (Pubitemid 28355143)
95. Raftogianis, R. B., Wood, T. C., Otterness, D. M., Van Loon, J. A., Weinshilboum, R. M. (1997). Phenol sulfotransferase pharma-cogenetics in humans: association of common SULT1A1 alle-les with TS PST phenotype. Biochem Biophys Res Commun 239:298-304. (Pubitemid 27480360)
96. Raftogianis, R. B., Wood, T. C., Weinshilboum, R. M. (1999). Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol 58:605-616. (Pubitemid 29296880)
97. Raijmakers, M. T., Jansen, P. L., Steegers, E. A., Peters, W. H. (2000). Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 33:348-351. (Pubitemid 30663370)
98. Rauchschwalbe, S. K., Zühlsdorf, M. T., Wensing, G., Kuhlmann, J. (2004). Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. Int J Clin Pharmacol Ter 42:73-77. (Pubitemid 38219917)
99. Raucy, J. L., Lasker, J. M., Lieber, C. S., Black, M. (1989). Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys 271:270-283. (Pubitemid 19145373)
100. Reiter, C., Weinshilboum, R. M. (1982). Platelet phenol sulfotrans-ferase activity: correlation with sulfate conjugation of acetaminophen. Clin Pharmacol Ter 32:612-621. (Pubitemid 13096705)
101. Roth, M. J., Dawsey, S. M., Wang, G. Q., Tangrea, J. A., Zhou, B., Ratnasinghe, D., et al. (2000). Association between GSTM1*0 and squamous dysplasia of the esophagus in the high-risk region of Linxian, China. Cancer Lett 156:73-81. (Pubitemid 30326770)
102. Rumack, B. H., Peterson, R. G. (1978). Acetaminophen overdose: incidence, diagnosis, and management in 416 patients. Pediatrics 62:898-903. (Pubitemid 9009962)
103. Sachse, C., Brockmöller, J., Bauer, S., Roots, I. (1997). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-295 (Pubitemid 27058401)
104. Saeki, M., Saito, Y., Jinno, H., Sai, K., Kaniwa, N., Ozawa, S., et al. (2005). Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet 20:85-90.
105. Seidgard, J., Vorachek, W. R., Pero, R. W., Pearson, W. R. (1988). Hereditary diferences in the expression of the human glutath-ione S-transferase activity on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85:7293-7297.
106. Sipe, J. C., Chiang, K., Gerber, A. L., Beutler, E., Cravatt, B. F. (2002). A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA 99:8394-8399. (Pubitemid 34651063)
107. Sommers, D. K., van Staden, D. A., Moncrief, J., Schoeman, H. S. (1985). Paracetamol metabolism in African villagers. Human Toxicol 4:385-389. (Pubitemid 15054658)
108. Strange, R. C., Fryer, A. A. (1999). Te glutathione S-tranferases: infu-ence of polymorphism on cancer susceptibility. IARC Sci Publ 148:231-249.
109. Tankanitlert, J., Morales, N. P., Howard, T. A., Fucharoen, P., Ware, R. E., Fucharoen, S., et al. (2007). Efects of combined UDP-glucuronosyltransferase (UGT) 1A1*28 and 1A6*2 on paracetamol pharmacokinetics in beta-thalassemia/HbE. Pharmacology 79:97-103. (Pubitemid 46555221)
110. Tomae, B. A., Rifki, O. F., Teobald, M. A., Ecklof, B. W., Wieben, E. D., Weinshilboum, R. M. (2003). Human catecholamine sul-fotransferase (SULT1A3) pharmacogenetics: functional genetic polymorphism. J Neurochem 87:809-819. (Pubitemid 37444557)
111. Tummel, K. E., Lee, C. A., Kunze, K. L., Nelson, S. D., Slattery, J. T. (1993). Oxidation of acetaminophen to N-acetyl-p-benzoquinone imine by human CYP3A4. Biochem Pharmacol 45:1563-1569. (Pubitemid 23130300)
112. Tonge, R. B., Kelly, E. J., Bruschi, S. A., Kalhorn, T., Eaton, D. L., Nebert, D. W., et al. (1998). Role of CYP1A2 in the hepatotoxicity of acetaminophen: investigation using Cyp1a2 null mice. Toxicol Appl Pharmacol 153:102-108. (Pubitemid 28563894)
113. Tukey, R. H., Strassburg, C. P. (2000). Human UDP- glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616. (Pubitemid 30340694)
114. Wang, S. L., Lee, H., Chen, K. W., Tsai, K. J., Chen, C. Y., Lin, P. (1999). Cytochrome P4502E1 genetic polymorphisms and lung cancer in a Taiwanese population. Lung Cancer 26:27-34. (Pubitemid 29469713)
115. Watanabe, A., Fukami, T., Takahashi, S., Kobayashi, Y., Nakagawa, N., Nakajima, M., et al. (2010). Arylacetamide deacetylase is a determinant enzyme for the diference in hydrolase activities of phenacetin and acetaminophen. Drug Metab Disposit 38:1532-1537.
116. Watkins, P. B., Kaplowitz, N., Slattery, J. T., Colonese, C. R., Colucci, S. V., Stewart, P. W., et al. (2006). Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized, controlled trial. JAMA 296:87-93.
117. Weinshilboum, R. M., Adjei, A. A. (2005). Sulfate conjugation: phar-macogenetics and pharmacogenomics. In: Pacifci, G. M., Coughtrie, M. W. H. (Eds.), Human cytosolic sulfotransferases (pp 61-78). Boca Raton, Florida, USA: CRC Press, Taylor and Francis Group.
118. Wu, X., Shi, H., Jiang, H., Kemp, B., Hong, W. K., Delclos, G. L., et al. (1997). Associations between cytochrome P4502E1 genotype, mutagen sensitivity, cigarette smoking, and susceptibility to lung cancer. Carcinogenesis 18:967-973. (Pubitemid 28132341)
119. Xue, Y, Sun, D, Daly, A, Yang, F, Zhou, X, Zhao, M, et al. (2008). Adaptive evolution of UGT2B17 copy-number variation. Am J Hum Genet 83:337-346.
120. Yin, O. Q., Tomlinson, B., Chow, A. H., Chow, M. S. (2001). Pharmacokinetics of acetaminophen in Hong Kong Chinese subjects. Int J Pharm 222:305-308. (Pubitemid 32568373)
121. Zaher, H, Buters, JT, Ward, JM, Bruno, MK, Lucas, AM, Stern, ST, et al. (1998). Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol Appl Pharmacol 152: 193-199. (Pubitemid 28498688)
122. Zhou, L., Erickson, R. R., Hardwick, J. P., Park, S. S., Wrighton, S. A., Holtzman, J. L. (1997). Catalysis of the cysteine conjugation and protein binding of acetaminophen by microsomes from a human lymphoblast line transfected with the cDNAs of various forms of human cytochrome P450. J Pharmacol Exp Ter 281:785-790. (Pubitemid 27203812)
123. Zhu, HJ, Patrick, KS, Yuan, HJ, Wang, JS, Donovan, JL, Devane, CL, et al. (2008). Two CES1 gene mutations lead to dysfunctional car-boxylesterase 1 activity in man: clinical signifcance and molecular basis. Am J Hum Genet 82:1241-1248.